Sanofi Consumer Healthcare India Limited has announced robust financial results for the quarter and year ended December 31, 2025, demonstrating strong operational performance across key metrics. The company published its audited financial results in Business Standard and Sakal newspapers on February 27, 2026.

Strong Quarterly Performance

The company delivered exceptional growth in Q4 FY25, with significant improvements across all major financial parameters. The quarterly results showcase the company's ability to maintain momentum in a competitive healthcare market.

Annual Financial Highlights

For the full financial year FY25, Sanofi Consumer Healthcare India maintained its growth trajectory with consistent performance improvements. The annual results reflect the company's strategic initiatives and market positioning in the consumer healthcare segment.

Sequential Quarter Performance

Comparing Q4 FY25 with the previous quarter (Q3 FY25), the company showed continued momentum with total income increasing from ₹2,369 million to ₹2,556 million, representing a 7.89% sequential growth. Net profit after tax also improved from ₹629 million in Q3 FY25 to ₹665 million in Q4 FY25.

Dividend Recommendation and Corporate Actions

The Board of Directors has recommended a final dividend of ₹75 per equity share of ₹10 face value for the year ended December 31, 2025. This dividend recommendation is subject to approval by shareholders at the upcoming Annual General Meeting.

Regulatory Compliance and Governance

The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and were reviewed by the Audit Committee before approval by the Board of Directors on February 25, 2026. The company maintains its commitment to transparency and regulatory compliance under SEBI listing requirements.

Sanofi Consumer Healthcare India Limited has delivered exceptional Q3 financial performance, demonstrating robust growth across key metrics. The consumer healthcare company reported strong quarterly results with net profit surging 50% year-on-year, reflecting the company's effective execution strategies and market strength.

Q3 Financial Performance Highlights

The third quarter results showcase remarkable growth momentum across all major financial parameters, with the company maintaining strong profitability and revenue expansion.

Revenue and Profitability Analysis

The company's revenue performance demonstrates strong market traction with total revenue reaching ₹2.50 billion compared to ₹1.70 billion in the corresponding quarter of the previous year. This substantial revenue growth of over 47% reflects the company's successful market strategies and product portfolio strength.

Net profit performance has been particularly impressive, with earnings jumping to ₹665 million from ₹443 million year-on-year. This 50% increase in profitability showcases the company's ability to effectively convert revenue growth into bottom-line results.

EBITDA Performance and Margin Analysis

EBITDA for the quarter reached ₹898 million, representing a significant increase from ₹621 million in the same period last year, marking a growth of 44.61%. However, the EBITDA margin contracted slightly to 35.78% from 36.38% in the previous year, indicating a marginal impact on operational efficiency despite strong absolute growth.

Market Position and Growth Trajectory

The strong quarterly performance reinforces Sanofi Consumer Healthcare's position as a leading player in the Indian consumer healthcare segment. The company's ability to deliver consistent growth across revenue and profitability metrics demonstrates its resilient business model and effective market execution capabilities.

The robust financial results reflect the company's strategic focus on core portfolio strength and operational excellence, positioning it well for sustained growth in the competitive consumer healthcare market.